Publications by authors named "A D Trobaugh-Lotrario"
Background: Specific patients with hepatoblastoma (HB) and hepatocellular carcinoma (HCC) do not meet eligibility criteria for Children's Oncology Group (COG) trials, limiting an understanding of how comorbidities affect the outcome. We define such a population for future-focused care improvements.
Methods: A questionnaire was sent to COG institutional principal investigators to obtain anonymized data regarding patients with a liver tumor diagnosis not enrolled on AHEP1531 due to ineligibility by trial criteria or other reasons (excluding parent/patient preference).
Article Synopsis
- This study looked at two ways to treat a type of liver cancer called hepatoblastoma in kids: doing surgery right away or giving chemotherapy first and then doing surgery later.
- They compared the results from over 500 patients to see which method worked better for survival and recovery.
- The study showed that both methods had similar results in terms of surgery success and complications, but some patients with certain conditions did better with surgery first.
Over 50% of patients with systemic LCH are not cured with front-line therapies, and data to guide salvage options are limited. We describe 58 patients with LCH who were treated with clofarabine. Clofarabine monotherapy was active against LCH in this cohort, including heavily pretreated patients with a systemic objective response rate of 92.
View Article and Find Full Text PDFArticle Synopsis
- Liver tumors represent about 2% of pediatric cancers, with hepatoblastoma (HB) showing a cure rate of 50-70% in advanced cases, while advanced hepatocellular carcinoma (HCC) has a less than 20% 5-year survival rate.
- A scoping review reveals a lack of solid data for managing relapsed pediatric HB and HCC, with existing trials often excluding critical patient demographics and having very few participants.
- To address these gaps, a global pediatric consortium is being formed to gather retrospective relapse data from over 100 institutions worldwide, which aims to guide future relapse trials.
Treatment intensification has improved survival in patients with hepatoblastoma (HB); however, these treatments are associated with an increased risk of late effects, including second malignant neoplasms (SMNs). Data is limited regarding SMNs following HB treatment. Cases of SMNs following treatment for HB reported in the literature and from personal communication were analyzed to further assess this late effect.
View Article and Find Full Text PDF